Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax (TM) delta inulin adjuvant
David L Gordon, Dimitar Sajkov, Yoshikazu Honda-Okubo, Samuel H Wilks, Malet Aban, Ian G Barr, Nikolai Petrovsky
Vaccine | ELSEVIER SCI LTD | Published : 2016
Awarded by National Institutes of Health, National Institute of Allergy and Infectious Diseases, United States
Awarded by Medical Research Council
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Development of Advax adjuvant was supported by Contracts U01-AI061142 and HHSN272200800039C from the National Institutes of Health, National Institute of Allergy and Infectious Diseases, United States. This publication's contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. We thank the clinical trial coordinators and research staff including Sharen Pringle and Kylie Bragg for their expert assistance. We thank Dr. Sue Heinzel for her contribution to study planning and implementation. We thank all the study subjects for their participation. We thank WHO Collaborating Centre for Reference and Research on Influenza Melbourne for supplying influenza typing kits.